Post Marketing Surveillance For General Drug Use To Assess the Safety And Efficacy Profile Of Viviant In Usual Practice

Pfizer logo

Pfizer

Status

Completed

Conditions

Osteoporosis

Treatments

Drug: Viviant

Study type

Observational

Funder types

Industry

Identifiers

NCT01793142
B1781047

Details and patient eligibility

About

This survey is conducted for preparing application material for re examination under the Pharmaceutical Affairs Laws and its Enforcement Regulation, and assessing the safety and efficacy profiles of VIVIANT in usual practice according to the Re-examination Regulation for New Drugs

Full description

continuous enrollment

Enrollment

3,430 patients

Sex

Female

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Postmenopausal osteoporosis and osteopenia patients

Exclusion criteria

  • Patients with active or past history of venous thromboembolic events including deep vein thrombosis,
  • Patients with pulmonary embolism and retinal vein thrombosis

Trial design

3,430 participants in 1 patient group

Viviant treatment group
Description:
Viviant treatment group
Treatment:
Drug: Viviant

Trial documents
1

Trial contacts and locations

60

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems